ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Design and characterization of phloretin-loaded PEG-lipid hybrid micelles for enhanced breast cancer therapy.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains a leading cause of mortality among women worldwide, emphasizing the urgent need for innovative therapeutic strategies. Phloretin, a natural dihydrochalcone flavonoid with potent anticancer activity, is limited by poor aqueous solubility and bioavailability. To overcome these challenges, phloretin was encapsulated in PEG-lipid hybrid micelles (PLHMs) formulated from PEG 4000, soy lecithin, and cholesterol. Optimization via a central composite design yielded the optimized formulation (F14), which exhibited a vesicle size of 190.6 ± 5.3 nm, a polydispersity index of 0.201 ± 0.01, and a zeta potential of - 28.5 ± 1.9 mV, indicating nanoscale uniformity and excellent colloidal stability. The formulation achieved an entrapment efficiency of 95.0 ± 1.6%, significantly higher than that of free phloretin. In vitro release studies demonstrated a biphasic release profile characterized by an initial burst followed by sustained release, with 67.2 ± 1.4% of the drug released over 24 h. Notably, phloretin solubility improved 2.2-fold compared to the pure compound. Cytotoxicity evaluation using the MTT assay on MCF-7 breast cancer cells revealed an IC₅₀ of 38 ± 2.8 μM for PLHMs, compared to 20 ± 1.5 μM for 5-fluorouracil. These findings highlight the promise of PLHMs as effective nanocarriers for phloretin, offering enhanced drug encapsulation, controlled release, and improved anticancer efficacy for breast cancer treatment.
Indexed as
Identifiers
41460317What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.